Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:32 2022-09-23 am EDT
309.30 CHF   -0.74%
09/22Novartis to prioritize U.S. market, unfazed by drug pricing pushback
RE
09/21ROCHE HOLDINGS AG : Deutsche Bank sticks Neutral
MD
09/20GLOBAL MARKETS LIVE : Apple, United Health, Ford, PepsiCo, Peloton...
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Enters Team-Up to Evaluate Pancreatic Cancer Drug Combo

08/10/2022 | 10:42am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
LISATA THERAPEUTICS, INC. -1.68% 4.69 Delayed Quote.-62.85%
ROCHE HOLDING AG -0.74% 309.3 Delayed Quote.-18.41%
All news about ROCHE HOLDING AG
09/22Novartis to prioritize U.S. market, unfazed by drug pricing pushback
RE
09/21ROCHE HOLDINGS AG : Deutsche Bank sticks Neutral
MD
09/20GLOBAL MARKETS LIVE : Apple, United Health, Ford, PepsiCo, Peloton...
MS
09/20Invitation to Roche's 3rd Quarter Sales 2022 Webinar
AQ
09/19Roche Gets US FDA Nod for Cobas System for Laboratories
MT
09/19Roche Holding AG Grants FDA Clearance for Cobas Pure Integrated Solutions for Low- to M..
CI
09/19MARKETSCREENER'S WORLD PRESS REVIEW : September 13, 2022
MS
09/19Genentech And Samsung Bioepis Settle Bevacizumab Biosimilar Patent Dispute
AQ
09/19Roche Gets EU's Nod For Vabysmo in Treatment of Two Vision Loss Diseases
MT
09/19European Commission Approves Roche Holding AG’s Vabysmo, the First Bispecific Anti..
CI
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 273 M 65 530 M 65 530 M
Net income 2022 14 747 M 15 035 M 15 035 M
Net Debt 2022 11 159 M 11 377 M 11 377 M
P/E ratio 2022 16,0x
Yield 2022 3,11%
Capitalization 254 B 259 B 259 B
EV / Sales 2022 4,13x
EV / Sales 2023 3,99x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 309,30 CHF
Average target price 377,16 CHF
Spread / Average Target 21,9%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-18.41%259 291
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392
NOVO NORDISK A/S1.95%221 838